Brown, Lisle/Cummings’s iShares Biotechnology ETF IBB Stock Holding History

Brown, Lisle/Cummings’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-270	Closed	-$35.2K	–	487
2022 Q1	$35.2K	Hold	270	–	–	0.02%	293
2021 Q4	$41.2K	Buy	+270	New	+$41.8K	0.02%	282

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Brown, Lisle/Cummings's IBB Position: Q2 2022 in Review

Brown, Lisle/Cummings sold out of iShares Biotechnology ETF (IBB) in Q2 2022, closing a stake of 270 shares — an estimated $35.2K sold.

Brown, Lisle/Cummings first reported a position in IBB in Q4 2021 and held it in 2 quarters. The position peaked at $41.2K in Q4 2021. 858 funds tracked by Wall St. Rank hold IBB as of Q2 2022.

Brown, Lisle/Cummings reported no remaining iShares Biotechnology ETF position as of Q2 2022 after selling out during the quarter.
Brown, Lisle/Cummings sold 270 iShares Biotechnology ETF shares in Q2 2022, an estimated $35.2K.
Brown, Lisle/Cummings first reported a position in iShares Biotechnology ETF in Q4 2021 and held it in 2 quarters.
Brown, Lisle/Cummings's iShares Biotechnology ETF position peaked at $41.2K in Q4 2021.
858 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2022.

Based on Brown, Lisle/Cummings's 13F filing for Q2 2022, filed 1 Jul 2024.